Organon & Co.

Case Overview
19 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 07/22/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Organon & Co. |
Court: | Court: District of New Jersey |
Case Number: | Case Number: 2:25cv05322 |
Class Period: | Class Period: 10/31/2024 - 04/30/2025 |
Ticker: | Ticker: OGN |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) securities during the period from October 31, 2024, through April 30, 2025 (“the Class Period”). Investors have until July 22, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On May 1, 2025, Organon published a press release detailing first quarter 2025 results and announced that management reset the Company’s dividend payout, from $0.28 to $0.02. Organon held an earnings call shortly after posting the results. However, statements made during the earnings call contradicted their earlier statements, including ones made during their October 31. 2024 and February 13, 2025, earnings call. During those calls, the Defendants reassured investors that the regular quarterly dividend was a number one priority and that the Company was committed to its capital allocation strategy through the aforementioned dividend. Further, Organon continually highlighted the Company’s prioritization of capital allocation by means of the quarterly dividends, while touting Organon’s acquisition of Dermavant and its key asset, VTAMA, minimizing any risk associated with the Company’s capital allocation strategy. On this news, the price of Organon shares declined by $3.48 per share, or approximately 26%, from $12.93 per share on April 30, 2025, to close at $9.45 on May 1, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose the true state of Organon’s priorities, particularly, related to capital allocation through quarterly dividends.
On May 1, 2025, Organon published a press release detailing first quarter 2025 results and announced that management reset the Company’s dividend payout, from $0.28 to $0.02. Organon held an earnings call shortly after posting the results. However, statements made during the earnings call contradicted their earlier statements, including ones made during their October 31. 2024 and February 13, 2025, earnings call. During those calls, the Defendants reassured investors that the regular quarterly dividend was a number one priority and that the Company was committed to its capital allocation strategy through the aforementioned dividend. Further, Organon continually highlighted the Company’s prioritization of capital allocation by means of the quarterly dividends, while touting Organon’s acquisition of Dermavant and its key asset, VTAMA, minimizing any risk associated with the Company’s capital allocation strategy. On this news, the price of Organon shares declined by $3.48 per share, or approximately 26%, from $12.93 per share on April 30, 2025, to close at $9.45 on May 1, 2025.
The complaint alleges that defendants, throughout the Class Period, failed to disclose the true state of Organon’s priorities, particularly, related to capital allocation through quarterly dividends.